Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Venture capitalist Vinod Khosla said artificial intelligence (AI) is rapidly expanding drug discovery, but traditional testing methods have failed to keep pace with the technology's progress. On Wednesday, in a post on X, Khosla said AI has produced what he described as a "21st-century hyperabundance of potential new drugs and biological hypotheses," while drug testing still relies heavily on conventional animal studies.
He argued that the industry needs a more human-relevant approach to evaluating potential treatments. "We are still using 18th-century style animal testing," Khosla wrote. A single bad hire can set a startup back years.
Here are the 5 hires founders most often misjudge — and why Still Learning the Market? These 50 Must-Know Terms Can Help You Catch Up Fast He pointed to Vivodyne, a biotechnology company developing technology to test drugs using living human tissues at scale. "Instead, @Vivodyne is evaluating drugs in living human tissues at industrial scale," Khosla said.
He also said he was excited to continue working with Vivodyne as the company develops its "Virtual Human" data center, which he said could eventually help researchers predict how patients will respond to treatments. AI has created a 21st-century hyperabundance of potential new drugs and biological hypotheses, but we are still using 18th-century style animal testing.Instead, @Vivodyne is evaluating drugs in living human tissues at industrial scale.Excited to continue working with Vivodyne… pic.twitter.com/Xc1EwWQ5bB — Vinod Khosla (@vkhosla) August 12, 2026 Trending: Avoid the #1 Investing Mistake: How Your 'Safe' Holdings Could Be Costing You Big Time Earlier, Anthropic, Takeda Pharmaceutical Co. Ltd., Nvidia Corp. and Eli Lilly and Co. highlighted the growing role of AI in drug discovery and medical research.
Anthropic launched Claude Science, an AI workbench that combined scientific literature analysis, computational biology, code generation and large-scale computing, with access to more than 60 scientific skills and connectors Takeda reported that its AI-developed psoriasis drug zasocitinib significantly outperformed Bristol-Myers Squibb Co.'s Sotyktu in a Phase 3 trial, with more than 35% of patients achieving complete skin clearance at week 16. Meanwhile, Nvidia and Eli Lilly announced a $1 billion AI co-innovation lab aimed at combining AI with biological research to accelerate drug development. Skip the Regrets: The Essential Retirement Tips Experts Wish Everyone Knew Earlier.
Think you're saving enough for your kids? You might be dangerously off — see why Building a resilient portfolio means thinking beyond a single asset or market trend. Economic cycles shift, sectors rise and fall, and no one investment performs well in every environment.
Extract — continue reading at the source.
